Overview: HIV-2 RNA Quantitative TestIntroduction: The HIV-2 RNA Quantitative Test measures HIV-2 viral load to monitor infection progression or treatment response, helping manage immune deficiency and prevent complications. Affecting 1 in 1,000,000 people in the U.S., HIV-2 poses diagnostic challenges due to limited testing. Following 2023 Centers for Disease Control and Prevention (CDC) guidelines, it uses RT-PCR for high accuracy, supporting virology screening. This test is vital for monitoring, treatment adjustment, and improving outcomes in infectious disease.
Other Names: HIV-2 Viral Load Test, HIV-2 RNA Assay.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic reliability.
Historical Milestone: HIV-2 viral load testing began in the 1990s with research by Soriano, who developed RT-PCR methods. RT-PCR advancements in the 2000s by Roche improved detection, surpassing earlier antibody tests.
Purpose: Measures HIV-2 RNA levels to monitor progression, guides antiretroviral therapy, and evaluates patients with HIV history, aiming to prevent complications.
Test Parameters: HIV-2 RNA levels
Pretest Condition: No special preparation required. Collect plasma. Report history of HIV infection.
Specimen: Plasma (EDTA, 2-4 mL); 2 mL plasma in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document recurrent infections or HIV history. Include current medications or treatment history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., AIDS), and sample collection risks.
Procedural Considerations: Uses RT-PCR to measure RNA, requiring labs with thermal cyclers. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: High RNA indicates progression, guiding therapy. Early adjustment might prevent complications, while uncontrolled levels lead to AIDS. Low levels suggest treatment success.
Specialist Consultation: Consult an infectious disease specialist for interpretation.
Additional Supporting Tests: HIV-2 Ab test, CD4 count, or genotyping to confirm diagnosis.
Test Limitations: Specific to HIV-2; correlation with clinical status needed. False negatives possible with low viral load.
References: CDC Guidelines, 2023; Journal of Clinical Microbiology, Soriano V, 2022.
